Results for: Pharmaceuticals

Sage Therapeutics has announced the discontinuation of further clinical development of its drug dalzanemdor for Alzheimer’s disease following disappointing results from the Phase 2 LIGHTWAVE study. The study failed to demonstrate a statistically significant difference in cognitive function between patients treated with dalzanemdor and those receiving placebo. This setback follows earlier failures in trials for dalzanemdor in Parkinson’s disease and the termination of a collaboration agreement with Biogen for another drug candidate, SAGE-324.

Martin Shkreli, the former pharmaceutical executive known as ‘Pharma Bro’, has faced another legal setback as the U.S. Supreme Court denied his appeal to overturn a $64.6 million repayment order. The decision reaffirms his liability for the profits gained through a fraudulent scheme and bars him from the pharmaceutical industry for life.

Italian pharmaceutical company Recordati has acquired the global rights to Enjaymo (sutimlimab), a treatment for cold agglutinin disease (CAD), from Sanofi for $825 million upfront and potential milestone payments of up to $250 million. The deal is expected to be immediately accretive to Recordati’s earnings and will be funded by existing cash and new debt facilities.

Thermo Fisher Scientific’s Greenville facility, a major contract drug manufacturing site, has been flagged for repeated regulatory violations despite its potential for growth in the injectables sector. While the FDA has not taken regulatory action, concerns remain about the plant’s quality control practices, particularly after recent issues with the production of Wegovy and Beyfortus.

Texas Attorney General Ken Paxton has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of conspiring to inflate insulin prices. The lawsuit alleges that manufacturers artificially raised prices while paying PBMs for preferred placement, ultimately harming diabetes patients and healthcare providers.

The global inhalable drugs market is expected to experience significant growth in the coming years, fueled by the increasing prevalence of respiratory diseases like asthma and COPD, as well as the rising use of inhalable medications for managing diabetes and Parkinson’s disease. This market analysis explores key trends, drivers, and challenges shaping this sector.

The global breast cancer treatment landscape is evolving rapidly, with over 100 pharmaceutical companies actively developing new therapies to combat this prevalent disease. DelveInsight’s ‘Breast Cancer Pipeline Insight 2024’ report highlights the robust pipeline, featuring 120+ potential breast cancer drugs in various stages of clinical development. This report provides a comprehensive overview of the latest advancements, key players, and promising therapies on the horizon.

Roche Holdings AG, a pharmaceutical giant, has outlined a new strategy to accelerate drug development, focusing on five priority areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, renal, and metabolism diseases. The company is prioritizing select assets with ‘exceptional potential’ and plans to fast-track clinical trials and expand into new indications. Roche also highlighted its ambitions in the obesity space, expecting its obesity drug candidates to generate over 3 billion Swiss francs in annual sales.

As central banks around the world, including the Federal Reserve and the European Central Bank, continue to lower interest rates, certain stocks stand to gain significantly. This article highlights three companies – Infineon Technologies, Novo Nordisk, and ASML Holdings – that are well-positioned to capitalize on this trend due to their growth strategies, innovative products, and favorable market conditions.

Merck (MRK) closed the trading day down 1.43%, lagging behind the broader market gains. While the company is projected to report strong earnings in the coming months, investors are cautious, leading to a recent stock decline. The article examines key financial data, analyst estimates, and valuation metrics to understand the current market sentiment surrounding Merck.